DailyUpdates for Breaking Research
DailyUpdates features breaking research judged by LeadDiscovery's editorial team to be of key importance to drug development. Papers are selected from over 10,000 published each week from most pear reviewed journals.
A list of headline articles featured over the past week are listed below.
To submit you paper to be listed on DailyUpdates contact LeadDiscovery.
Research featured over the past 5 days
- Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells.
- MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway.
- Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
- Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
- A Phase II Study of Lipoplatin (Liposomal Cisplatin)/Vinorelbine Combination in HER-2/neu-Negative Metastatic Breast Cancer.
- Synthesis and biological evaluation of potential new inhibitors of the bacterial transferase MraY with a β-ketophosphonate structure.
- IMATINIB AMELIORATES RENAL MORPHOLOGICAL CHANGES IN CYP1A1-REN2 TRANSGENIC RATS WITH INDUCIBLE ANG II-DEPENDENT MALIGNANT HYPERTENSION.
- PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ.
- Cyr61 expression in Osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice.
- Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.
- N-acetylglucosamine inhibits T-helper 1 (Th1) / T-helper 17 (Th17) responses and treats experimental autoimmune encephalomyelitis.
- Serotonin-receptor-3-antagonists improve obesity-associated fatty liver disease in mice.
- Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies.
- A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
- C-122, a novel antagonist of serotonin receptor 5-HT(2B), prevents monocrotaline-induced pulmonary arterial hypertension in rats.
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.
- Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.
- miR-143 Overexpression Impairs Growth of Human Colon Carcinoma Xenografts in Mice with Induction of Apoptosis and Inhibition of Proliferation.
- Integrated safety in tocilizumab clinical trials.
- Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.